Benefits
Studied only in stroke patients, not in healthy people
The only human research cited on this page is two small Russian-language studies in people recovering from a stroke, published in 2005 and 2010 in a Russian neurology and psychiatry journal. They reported improvement in neurological deficits and in cognitive function in those patients. Stroke rehabilitation is specialist medical care, and results there say nothing about what this compound does for a healthy person. Neither study is available in full in English, so group sizes, randomization and blinding cannot be checked.
Fatigue and low energy: not supported by the studies cited here
No study cited on this page tests phenylpiracetam for everyday tiredness, chronic fatigue syndrome or fatigue after head injury. Both references are stroke rehabilitation trials. Russian regulators do list fatigue-type conditions among the approved uses of the prescription medicine Phenotropil, but a regulatory listing in one country is not evidence you can check, and none of it applies to a healthy person looking for more energy.
Origins in the Soviet space program
Phenylpiracetam was developed in the Soviet Union in the 1980s, and its reported use in the space program is part of its history rather than evidence of a benefit. No study cited on this page measured stamina, cold tolerance or mental performance in healthy people. Being banned in sport is an anti-doping classification decision, not proof that the compound improves performance.
Cognitive problems after stroke: a supervised medical use, not a consumer one
The evidence cited here covers one situation only: people recovering from a stroke, treated in a Russian medical setting. No study on this page involves head injury, brain surgery or any other cause of cognitive decline. Stroke and brain injury need specialist care, and nothing here is a reason for a healthy person to take this compound for memory or focus.
Epilepsy: no verifiable study is cited
The reference list on this page contains no epilepsy study. Any use alongside anti-seizure medication belongs to Russian prescribing practice under a neurologist's supervision. People with epilepsy should never add or change anything without their doctor, since stimulant-like compounds and seizure medicines can interact.
Banned in sport: doping violation risk
Carphedon, the sport-testing name for phenylpiracetam, is on the World Anti-Doping Agency Prohibited List as a stimulant, and athletes have been sanctioned for it. If you are drug tested at any level, taking this risks a doping violation. Appearing on a banned list is a regulatory classification, not evidence that it makes anyone faster or stronger.
Mechanism of action
Dopamine reuptake inhibition (stimulant mechanism)
Laboratory and rodent work suggests phenylpiracetam slows the reuptake of dopamine, which sets it apart from other racetams and may explain its stimulant-like feel. The finding on effort-based responding comes from rats. None of this has been shown to produce a measurable benefit in people, and a mechanism is not evidence of an effect.
Multi-receptor neurotransmitter modulation
Laboratory work suggests it also affects several other brain signalling systems, and the added phenyl group appears to help it cross into the brain more readily than piracetam. These are preclinical observations. They do not demonstrate calming, cognitive or brain-protective effects in people, and no human study on this page tested any of them.
Locomotor activity stimulation
In rodents, phenylpiracetam increases movement and activity in a way that resembles a mild stimulant, with one mirror-image form more active than the other. These are animal findings. More movement in a cage is not the same as better physical performance in a person.
Cold tolerance: claimed, not demonstrated here
Cold tolerance is often mentioned in accounts of this compound's origins, but no study cited on this page measured it, in animals or in people. Treat it as an unverified claim.
Brain protection: animal models only
Animal models of reduced blood flow to the brain have been used to compare phenylpiracetam with piracetam. Those are laboratory models in animals, not people. Russian doctors do prescribe it after stroke, but the two human studies cited here are small, Russian-language, and cannot be checked in detail from their English abstracts.
Clinical trials
Russian-language report attributed to Gustov and colleagues, 2006, in Zh Nevrol Psikhiatr Im S S Korsakova. No PubMed ID is given for it, and it is not one of the two references listed on this page.
Hospital patients with blood-vessel-related brain disease, treated under medical care. The number of participants, how they were assigned to groups and whether anyone was blinded are not available in English.
The report describes reduced neurological deficits and better memory and attention compared with a control group. Because the full text is Russian-language and no PubMed ID is provided, the result cannot be independently checked, group sizes are unknown, and it was conducted in patients under medical care rather than in healthy adults.
Russian-language report attributed to Lybzikova and colleagues, 2008, in Zh Nevrol Psikhiatr Im S S Korsakova. No PubMed ID is given, and it is not among the two references listed on this page.
People with diagnosed epilepsy already taking anti-seizure medication, treated by doctors. The number of participants and the study design are not available in English.
The report describes fewer seizures and better cognitive function. It cannot be verified, no control group or blinding is described in what is available in English, and it concerns a diagnosed medical condition managed with prescription drugs. Nothing here applies to a healthy person.
Preclinical pharmacology study (Zvejniece L, Svalbe B, Veinberg G, Grinberga S, Vorona M, Kalvinsh I, Basic Clin Pharmacol Toxicol 109(5):407-412, doi:10.1111/j.1742-7843.2011.00742.x).
Rodents, not people. The two mirror-image forms of phenylpiracetam were compared for movement, behaviour in a depression-type test, and memory tasks.
In rats, the R form increased movement at 10 to 50 mg/kg and produced antidepressant-type effects in a behavioural test at 50 to 100 mg/kg, and it was more active than the S form. These are animal doses and animal behaviour tests. They do not show that phenylpiracetam lifts mood or boosts energy in people, and no human mood study is cited on this page.